Background: Limited treatments are available for persistent erythema of rosacea.
Rosacea is a chronic dermatologic disease affecting approximately 16 million adults in the United States. 1, 2 It is characterized by centrally distributed persistent facial erythema, flushing, telangiectasia, and inflammatory papules and pustules and may progress in later stages to more severe, disfiguring forms, such as rhinophyma. 1, [3] [4] [5] For many patients, the psychosocial impact of these manifestations as well as the clinical aspects of rosacea are significant. 6, 7 Dysregulation in the cutaneous vasomotor response may be responsible for flushing and persistent erythema. 8 When a stimulus such as heat, spicy food, a hot beverage, or emotional stress triggers this response, an abnormal dilation of facial blood vessels results, over time contributing to development of persistent facial erythema. 9, 10 Most topical pharmacologic agents approved by the US Food and Drug Administration for treatment of papules and pustules of rosacea have no effect on persistent facial erythema. 10 Oxymetazoline is an a 1A -adrenoceptor agonist and vasoconstrictor of the cutaneous microvasculature 11, 12 that is US Food and Drug Administratione approved for the topical treatment of persistent facial erythema associated with rosacea in adults. 13 This report describes findings from REVEAL Long-term, a phase 3, open-label clinical trial designed to evaluate the safety and efficacy of 52 weeks of treatment with oxymetazoline hydrochloride cream 1.0% (oxymetazoline) for moderate-to-severe persistent facial erythema associated with rosacea (National Clinical Trials identifier NCT02095158, registered March 21, 2014).
METHODS

Study design
This study was conducted at 25 centers within the United States. Recruitment took place between April 9, 2014, and August 19, 2014 . Study participants completed 6 visits (on study day 1 [baseline] and at weeks 4, 12, 26, 39, and 52]); patients received no medication during a 2-week post-treatment followup period. The study was performed in accordance with the Declaration of Helsinki and Good Clinical Practice and was approved by an institutional review board. All patients provided written informed consent before study entry.
Study treatment
On day 1, patients received treatment with oxymetazoline to be applied topically to the face once daily for 52 weeks. Patients were instructed to apply a pea-sized amount of medication in a thin layer covering the entire face, including the forehead, nose, cheeks, and chin, at the same time every morning.
Study patients
Eligible patients included adults age 18 years or older with moderate-to-severe persistent facial erythema of rosacea, defined as grade 3 or higher on the Clinician Erythema Assessment (CEA) scale with photonumeric guide and Subject SelfAssessment for rosacea facial redness (SSA) scale with photo guide.
Patients were excluded if they had facial hair, tattoos, or other characteristics that would interfere with erythema assessment; other dermatologic conditions within the treatment area; or uncontrolled systemic disease. There were no restrictions on the number of inflammatory lesions. Patients were not eligible if they had a history of drug abuse; Raynaud syndrome; narrow-angle glaucoma; orthostatic hypotension; cerebral or coronary insufficiency; thromboangiitis obliterans; scleroderma; Sj€ ogren syndrome; severe, unstable, or uncontrolled cardiovascular disease; or hypersensitivity to oxymetazoline.
Prohibited treatments included monoamine oxidase inhibitors or niacin in doses of 500 mg/d or higher; oxymetazoline-containing products, topical glucocorticosteroids applied to the face, systemic or nasal corticosteroids, or any acne product in the past 14 days; isotretinoin in the past 180 days; or any previous or current use of brimonidine topical gel, 0.33%. Patients were permitted to use therapies for inflammatory lesions of rosacea.
Study assessments
Safety. Treatment-emergent adverse events (TEAEs) were recorded at each study visit. The following safety measurements were assessed before the dose on day 1 and at weeks 4, 12, 26, 39, and 52 (or early exit): mean change from baseline in inflammatory lesion counts; Clinician Telangiectasia Assessment (CTA) score, rated on a 5-point scale; and evaluation of inflammatory lesions of rosacea using the Investigator's Global Assessment of
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Disease Severity, rated on a 5-point scale. Application-site skin blanching, rated on a 5-point scale, and dermal tolerability, including patient-rated stinging/burning (prickling pain sensation) and pruritus and investigator-rated scaling and dryness scored from 0 (none) to 3 (severe), were assessed before the dose and at hour 6 on day 1 and at weeks 4, 26, and 52 (or early exit), as well as before the dose at weeks 12 and 39. Vital signs were recorded before the dose at each study visit.
Rebound effect. Worsening of erythema from baseline after treatment cessation (rebound effect) was evaluated by change in CEA and SSA composite scores and individual scores from moderate (3) to severe (4). Analyses were conducted by using data from the week 52 visit (or early exit) before the dose, week 54 visit (or study exit) at 2 weeks after treatment, and at all unscheduled visits during the post-treatment period. Patients were instructed to call the study centers for an unscheduled visit any time during the 2-week follow-up period if they experienced increased erythema beyond their baseline level.
Efficacy. Efficacy was assessed by the proportion of patients achieving a clinical response, which was defined as a 2-grade or greater improvement (composite success) from baseline (before the dose on day 1) on the CEA and SSA at 3 and 6 hours after the dose on day 1 and at weeks 4, 26, and 52 (Table I   14 ). Statistical analysis. Safety analyses were conducted in all patients who received 1 or more applications of oxymetazoline. TEAEs were coded using the Medical Dictionary for Regulatory Activities, version 18.0. Efficacy analyses were conducted in the modified intent-to-treat population, which included enrolled patients with 1 or more CEA assessments and 1 or more SSA assessments after day 1 (baseline). No statistical testing was performed.
RESULTS
Patient disposition and demographics
Efficacy and safety were assessed in all 440 enrolled patients. Most patients were female, most were white, and the mean age was 53.1 years (Table II) . The most frequently used concomitant medications for rosacea ([1%) were doxycycline 
Safety and tolerability
Overview. During the entire study period, TEAEs were reported by 192 patients (43.6%) (Table III) ; most were mild or moderate in severity. Application-site TEAEs were the most commonly reported TEAEs during the study period (n = 70 [15.9%]). Among the 32 patients who received concomitant medications for rosacea, 21 (65.6%) reported TEAEs. No clinically meaningful differences were observed when comparing this subgroup to the entire study population.
Serious AEs occurred in 15 patients (3.4%); none was considered related to study treatment or led to discontinuation. The most commonly reported serious AE was basal cell carcinoma (n = 6 [1.4%]). All other serious AEs were reported in 1 patient (0.2%) each.
The number of discontinuations due to AEs was low (n = 14 [3.2%]) and included application-site dermatitis (n = 6 [1.4%]); application-site erythema The scales described here are the same as those used in 2 identically designed, randomized, double-blind, vehiclecontrolled, 29-day, phase 3 trials of oxymetazoline.
14 CEA, Clinician Erythema Assessment; SSA, Subject Self-Assessment. *CEA and SSA assessments were made using a photonumeric guide and photo guide, respectively; postbaseline assessments were made by clinicians and patients without access to the baseline photo. y Normal, healthy skin color as observed in individuals without rosacea.
Abbreviations used:
AE: adverse event CEA:
Clinician Erythema Assessment CTA:
Clinician Telangiectasia Assessment SSA:
Subject No clinically meaningful changes in vital signs were observed.
Treatment-related TEAEs. The incidence of TEAEs considered treatment related by the investigator was 8.2%, and the most common were application-site dermatitis, paresthesia, pain, and pruritus (Table IV) . Application-site erythema was considered treatment related in 0.7% of patients; flushing was not reported. The incidence of treatment-related TEAEs was highest during the first 90 days of treatment (5.9%) and lower in the 3 subsequent 90-day periods (1.5%, 0.7%, and 0.3%, respectively). Most treatment-related TEAEs were mild or moderate; those considered severe were application-site dermatitis (n = 3 [0.7%]) and application-site pain, application-site erythema, and photosensitivity (n = 1 [0.2%] each).
Skin blanching, inflammatory lesion counts, telangiectasia, and disease severity. No clinically meaningful changes were observed in skin blanching, inflammatory lesion counts, or CTA ratings during the treatment period. No severe blanching (unacceptable paleness) was observed during the 52 weeks. One patient experienced moderate skin blanching (much paler than normal) at week 26 hour 6.
The mean inflammatory lesion count was 3.5 at baseline and decreased to mean counts in the range of 1.5 to 2.9 at all postbaseline time points.
The proportions of patients with CTA ratings of clear skin, almost clear skin, and mild telangiectasia were consistent throughout the 52-week period. No substantive shift toward more severe CTA ratings was observed. CTA ratings of moderate and severe were observed in 19.8% and 3.9% of patients, respectively, at baseline and in 22.9% and 2.9% of patients, respectively, at week 52.
During the treatment period, 38.4% of patients (167 of 435) had a 1-grade or greater worsening from baseline in disease severity as related to inflammatory lesions for 1 or more visits, as recorded by the Investigator's Global Assessment of Disease Severity. On a per-visit basis, the percentage of patients with a 1-grade or greater worsening from baseline decreased from 18.5% at week 4 to 12.3% at week 52 (or early exit). Dermal tolerability. At week 52, low proportions of patients exhibited a 1-grade or greater worsening of patient-reported itching and burning/ stinging and investigator-rated dryness and scaling (Table V) .
Rebound effect. Low proportions of patients experienced a post-treatment rebound effect as assessed by the composite CEA and SSA (2 patients each [0.7%] at weeks 52 and 54 after treatment). Following treatment cessation, similar proportions of patients experienced worsening of erythema at week 52 before the dose and week 54 after treatment as assessed by CEA (4.5% and 4.7%, respectively) or SSA (1.4% and 0.9%, respectively). No patient requested an unscheduled visit on account of worsening of erythema during the 2-week posttreatment period.
Efficacy
Oxymetazoline demonstrated continued efficacy, with increasing proportions of patients experiencing improvement in erythema, defined as a 2-grade or greater composite improvement in CEA and SSA scores, 3 and 6 hours after application of the study medication compared with the predose day 1 (baseline) assessment, from day 1 through week 52 of treatment (Fig 1). Fig 2 shows images of 2 patients treated with oxymetazoline.
DISCUSSION
During the 52-week treatment period, oxymetazoline applied once daily was associated with low rates of discontinuation due to AEs, a low incidence of TEAEs, and a favorable dermal tolerability profile, and it maintained efficacy in patients with persistent facial erythema associated with rosacea.
Persistent facial erythema involves a complex pathophysiology of neurovascular dysregulation, enhanced immune response, and alteration of the cutaneous vasculature. 15 Modifications in the superficial cutaneous vasculature are regulated primarily by the sympathetic nervous system. [15] [16] [17] Oxymetazoline causes vasoconstriction primarily by activating a 1A -adrenoceptors; conversely, brimonidine (Mirvaso, Galderma Laboratories, Fort Worth, TX), which is another treatment for persistent erythema of rosacea, causes vasoconstriction through a 2 -adrenoceptors. 11, 12, 15, 18 Vascular smooth muscle cells express a 1 -adrenoceptors postsynaptically; thus, activation by an a-adrenoceptor agonist results in vasoconstriction. 16 In contrast, a 2 -adrenoceptors may be expressed presynaptically and/or postsynaptically, depending on vessel type. 16, 17 Activation of postsynaptic a 2 -adrenoceptors in the vascular smooth muscle causes vasoconstriction, but activation of presynaptic a 2 -adrenoceptors or a 2 -adrenoceptors in the vascular endothelium results in vasodilation, which may counteract the vasoconstrictor effect. Differences in mechanism of action between oxymetazoline, an a 1A -adrenoceptor agonist, 11, 12 and brimonidine, a selective a 2 -adrenoceptor agonist, 18 may contribute to differences in their safety profiles observed in the respective long-term safety studies. 19 In an open-label study of brimonidine, 0.33% (brimonidine tartrate 0.5%) topical gel, 11, 20 449 patients with rosacea were given a once-daily dose for up to 12 months. 19 Thirty-eight percent of patients discontinued treatment early, most often because of AEs (17%). 19 Overall, treatmentrelated AEs occurred in 31% of patients in the brimonidine open-label study; the most commonly reported treatment-related AEs were flushing (9%), worsening of erythema (7%), worsening of rosacea (4%), skin burning sensation (3%), skin irritation (3%), contact dermatitis (2%), and pruritus (2%). Conversely, in the present study of oxymetazoline, 17% of patients discontinued treatment early, with only 3% discontinuing treatment on account of an AE. Treatment-related AEs occurred in 8% of patients; the most commonly reported were application-site TEAEs: dermatitis (2%), paresthesia (2%), pain (1%), and pruritus (1%). Rebound effect was observed in 0.7% of patients, and flushing was not reported. However, because clinical trials are conducted under widely varying conditions, the AE rates cannot be directly compared with rates in clinical trials of another drug. No studies have been conducted to compare efficacy and safety profiles of topical oxymetazoline and brimonidine. 14 The open-label design of the present study precludes application of comparative statistics to demonstrate long-term efficacy of topical oxymetazoline cream for the treatment of persistent erythema associated with rosacea. Because oxymetazoline was demonstrated to be more effective than vehicle in the REVEAL 1 and 2 trials, it is likely that similar results would be observed in a longer-term study. J AM ACAD DERMATOL VOLUME 78, NUMBER 6 efficacy of oxymetazoline cream 1.0% for patients with moderate-to-severe persistent erythema associated with rosacea. On the basis of the overall safety profile and rigorous post-treatment follow-up, no clinically relevant rebound effect was observed.
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